Enlarge image
Biontech headquarters in Mainz
Photo: Sebastian Gollnow / dpa
The Mainz-based pharmaceutical company Biontech is making huge profits with its vaccine.
The public coffers in Rhineland-Palatinate also benefit from this - so much so that the federal state becomes a donor state.
In the financial equalization of the federal states, Rhineland-Palatinate rises from recipient country to donor country.
In 2020, Rhineland-Palatinate received 334 million euros from the financial equalization;
by the end of November 2021, however, 155 million euros were in the state’s donor account, as the “Frankfurter Allgemeine Zeitung” reports.
More than seven billion in profit in the first three quarters of 2021
This development is mainly due to the extremely good business of the corona vaccine manufacturer Biontech, the newspaper writes.
Biontech made a profit of more than seven billion euros in the first three quarters of last year alone.
The group had already given the state capital Mainz, where it is based, a real windfall last year: Huge trade tax revenues turned the originally expected deficit into a plus of more than one billion euros in the city coffers in 2021.
The state financial equalization system is a system in which funds from financially strong federal states are redistributed to poorer states.
col/AFP